Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Eiffage ( (FR:FGR) ) has provided an announcement.
Eiffage has secured a 50.8 million euro contract to design and build the Institute of Biology and Pathology at the Bordeaux University Hospital. The project, involving multiple architectural and engineering firms, emphasizes energy efficiency and environmental responsibility, including the use of low-carbon materials and bio-sourced elements. Construction is set to begin in September 2025 on an occupied site, with a completion target by 2028, reflecting Eiffage’s commitment to sustainable building practices.
More about Eiffage
Eiffage is a leading European company in construction and concessions, engaging in areas like construction, real estate, civil engineering, and energy systems. It has a workforce of 78,200 employees and achieved a 2023 turnover of 21.8 billion euros. Eiffage Construction, a subsidiary, specializes in urban planning, real estate development, and maintenance, with a strong presence in France and several European countries.
YTD Price Performance: 4.57%
Average Trading Volume: 90,579
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €8.62B
For a thorough assessment of FGR stock, go to TipRanks’ Stock Analysis page.
